A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer
CONCLUSIONS: Adding ipilimumab to AAPA did not improve outcomes in men with androgen responsive mCRPC. Despite the addition of carboplatin+cabazitaxel, men in the Unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups, to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.PMID:38683200 | DOI:10.1158/1078-0432.CCR-23-3740 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 29, 2024 Category: Cancer & Oncology Authors: Ana M Aparicio Rebecca S S Tidwell Shalini S Yadav Jiun-Sheng Chen Miao Zhang Jingjing Liu Shuai Guo Patrick G Pilie Yao Yu Xingzhi Song Haswanth Vundavilli Sonali Jindal Keyi Zhu Paul V Viscuse Justin M Lebenthal Andrew W Hahn Rama Soundararajan Paul G C Source Type: research
Extreme hypofractionated stereotactic radiotherapy for localized prostate Cancer: Efficacy and late urinary toxicity according to transurethral resection of the prostate history
CONCLUSION: Extreme hypofractionated SBRT is effective for localized prostate cancer with a low risk of late toxicity. A history of TURP is associated with a higher risk of late urinary toxicity. These findings may contribute to the optimal management of patients treated with this regimen, particularly those with a history of TURP.PMID:38681137 | PMC:PMC11047194 | DOI:10.1016/j.ctro.2024.100779 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 29, 2024 Category: Cancer & Oncology Authors: Maxime Galienne S éverine Risbourg Thomas Lacornerie Alexandre Taillez Eric Lartigau Ma ël Barthoulot David Pasquier Source Type: research
Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer
CONCLUSION: Men diagnosed in 2011-2016 with low-risk and favourable intermediate-risk PCa have a similar relative benefit but smaller absolute benefit of curative treatment compared to men diagnosed in 2000-2005.PMID:38682731 | DOI:10.2340/sju.v59.34015 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - April 29, 2024 Category: Urology & Nephrology Authors: Frederik F Thomsen Hans Garmo Lars Egevad P är Stattin Klaus Brasso Source Type: research
Role of antihypertensive medicines in prostate cancer: a systematic review
Hypertension is associated with the risk of prostate cancer (PCa) and its progression, however, it remains unclear whether antihypertensive medicines alter PCa risk or prognosis. This systematic review evaluat... (Source: BMC Cancer)
Source: BMC Cancer - April 29, 2024 Category: Cancer & Oncology Authors: Chinonyerem O. Iheanacho and Okechukwu Harrison Enechukwu Tags: Research Source Type: research
HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis
In recent years, there has been an increase in the incidence and mortality rates of prostate cancer (PCa). However, the specific molecular mechanisms underlying its occurrence and development remain unclear, n... (Source: BMC Cancer)
Source: BMC Cancer - April 29, 2024 Category: Cancer & Oncology Authors: Lihong Yang, Yong Ruan and Houqiang Xu Tags: Research Source Type: research
Alpha and Beta Radiation for Theragnostics
Targeted radionuclide therapy (TRT) has significantly evolved from its beginnings with iodine-131 to employing carrier molecules with beta emitting isotopes like lutetium-177. With the success of Lu-177-DOTATATE for neuroendocrine tumors and Lu-177-PSMA-617 for prostate cancer, several other beta emitting radioisotopes, such as Cu-67 and Tb-161, are being explored for TRT. The field has also expanded into targeted alpha therapy (TAT) with agents like radium-223 for bone metastases in prostate cancer, and several other alpha emitter radioisotopes with carrier molecules, such as Ac-225, and Pb-212 under clinical trials. Desp...
Source: PET Clinics - April 29, 2024 Category: Radiology Authors: Hong Song, George Sgouros Source Type: research
Refining clinical decision strategies and prostate cancer detection through fine adjustments in the combination of PSA-derived parameters and MRI
(Source: European Radiology)
Source: European Radiology - April 29, 2024 Category: Radiology Source Type: research
Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study
AbstractA 5-tier grouping of Gleason scores has recently been proposed. Studies have indicated prognostic heterogeneity within these groups. We assessed prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) for men diagnosed with Gleason score 3 + 5 = 8, 4 + 4 = 8 and 5 + 3 = 8 acinar adenocarcinoma on needle biopsy in a population-based national cohort. The Prostate Cancer data Base Sweden 5.0 was used for survival analysis with PCSM and ACM at 5 and 10 years as endpoints. Multivariable Cox regression models contr olling for socioeconomic factors, stage and primary treatment typ...
Source: Virchows Archiv - April 29, 2024 Category: Pathology Source Type: research
Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study)
Prostate Cancer and Prostatic Diseases, Published online: 29 April 2024; doi:10.1038/s41391-024-00833-zTwo-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study) (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - April 29, 2024 Category: Urology & Nephrology Authors: Steven A. Kaplan Jared L. Moss Sheldon J. Freedman Source Type: research
Benign prostatic hyperplasia during active surveillance for prostate cancer: is it time to define management strategies?
Prostate Cancer and Prostatic Diseases, Published online: 29 April 2024; doi:10.1038/s41391-024-00837-9Benign prostatic hyperplasia during active surveillance for prostate cancer: is it time to define management strategies? (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - April 29, 2024 Category: Urology & Nephrology Authors: Eugenio Bologna Leslie Claire Licari Francesco Ditonno Rocco Simone Flammia Aldo Brassetti Costantino Leonardo Antonio Franco Cosimo De Nunzio Riccardo Autorino Source Type: research
Outcomes Following Localized Prostate Cancer Treatment —Reply
In Reply In response to our recent article, Drs Huang and Ding question the validity of using questionnaires to assess sexual function. While a patient ’s responses are subjective (ie, indicating how their function seems to them rather than it being measured more objectively), the use of standardized, validated instruments for patient-reported outcomes remains the standard for both clinical and research purposes. Furthermore, any subjectivity-bas ed misclassification would be expected to be nondifferential and, therefore, should not affect our comparative results. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 29, 2024 Category: General Medicine Source Type: research
Outcomes Following Localized Prostate Cancer Treatment
To the Editor In a recent article that compared adverse outcomes of localized prostate cancer treatment modalities, persistent urinary incontinence after radical prostatectomy was highlighted as a significant difference compared with other therapeutic options. However, the authors overlooked the existence of safe and effective curative options for postprostatectomy incontinence management. When pelvic floor muscle training after prostatic surgery is ineffective for postprostatectomy incontinence, various surgical options such as the artificial urinary sphincter or minimally invasive alternatives such as periurethral balloo...
Source: JAMA - Journal of the American Medical Association - April 29, 2024 Category: General Medicine Source Type: research
Outcomes Following Localized Prostate Cancer Treatment
To the Editor A recent study reported approximately 10-year follow-up data on functional outcomes of patients after treatment for localized prostate cancer, providing essential evidence-based medical evidence for clinical decision-making. We have 2 concerns regarding the data analyses on sexual function after radical prostatectomy. First, apart from androgen deprivation therapy, the potential influence of salvage radiotherapy on sexual function also needs to be considered because this therapy is frequently used after radical prostatectomy in clinical settings, especially among patients with unfavorable-prognosis prostate c...
Source: JAMA - Journal of the American Medical Association - April 29, 2024 Category: General Medicine Source Type: research
Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals
PET Clin. 2024 Apr 27:S1556-8598(24)00026-9. doi: 10.1016/j.cpet.2024.03.011. Online ahead of print.ABSTRACTProstate cancer is the most common malignancy in men worldwide, with an estimated 174,650 new cases per year in the United States, and the second cancer-related cause of death, after lung cancer, with 31,620 deaths per year. While the 5 year survival rate for prostate cancer in patients without metastatic spread is nearly 100%, those with distant metastases have 5 year survival rates of approximately 30%. Initial diagnosis and assessment are based on PSA levels, Gleason score (derived from prostate biopsy), and advan...
Source: Clinical Prostate Cancer - April 28, 2024 Category: Cancer & Oncology Authors: Yaniv Yechiel Alexandre Chicheportiche Zohar Keidar Simona Ben-Haim Source Type: research
Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals
PET Clin. 2024 Apr 27:S1556-8598(24)00026-9. doi: 10.1016/j.cpet.2024.03.011. Online ahead of print.ABSTRACTProstate cancer is the most common malignancy in men worldwide, with an estimated 174,650 new cases per year in the United States, and the second cancer-related cause of death, after lung cancer, with 31,620 deaths per year. While the 5 year survival rate for prostate cancer in patients without metastatic spread is nearly 100%, those with distant metastases have 5 year survival rates of approximately 30%. Initial diagnosis and assessment are based on PSA levels, Gleason score (derived from prostate biopsy), and advan...
Source: Clinical Lung Cancer - April 28, 2024 Category: Cancer & Oncology Authors: Yaniv Yechiel Alexandre Chicheportiche Zohar Keidar Simona Ben-Haim Source Type: research
